This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C19 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the date of cancer registration) |
| B. Synonyms | Rectosigmoid junction cancer, adenocarcinoma of the rectosigmoid junction, RS junction cancer, Rectosigmoid colon cancer |
| C. Adult onset | Very high — mainly in the 50s–70s; clinical features intermediate between colon cancer and rectal cancer |
| 1. History | Anatomic definition of the rectosigmoid junction, evolution of ICD classification, controversy over rectal vs. colon cancer treatment decisions |
| 2. Causes | Same as colon and rectal cancer: diet, obesity, alcohol, smoking, hereditary syndromes (Lynch, FAP) |
| 3. Genetics | APC, KRAS, TP53 and SMAD4 mutations, MSI-H, BRAF V600E, Lynch and FAP hereditary predisposition |
| 4. General epidemiology | About 10–15% of all colorectal cancers (C18–C20); reflects features of left-sided colon cancer; several thousand cases per year in Korea |
| 5. Pathophysiology | Adenoma–carcinoma sequence (Vogelstein), serrated pathway, Lynch MMR pathway; left-sided colon features |
| 6. Symptoms | Bloody stools, change in bowel habits, abdominal pain, sensation of incomplete evacuation, narrowing of stool caliber, bowel obstruction, weight loss |
| 7. Signs | Digital rectal examination, abdominal mass, anemia, elevated CEA, CT findings of obstruction, proctoscopic findings |
| 8. Screening | National screening (fecal occult blood test from age 50 → colonoscopy), early endoscopy for high-risk groups, Lynch and FAP surveillance |
| 9. Diagnosis | Colonoscopy + biopsy, MRI (pelvis), CT, PET-CT, TNM (AJCC 8th edition), molecular marker testing |
| 10. Treatment | Sigmoid colon–rectal resection (anterior resection principle), consideration of neoadjuvant radiotherapy, FOLFOX/FOLFIRI + targeted therapy or immunotherapy |
| 11. Prognosis | 5-year survival similar to colon cancer (by stage, stage I 90%+ to stage IV 10–15%); treatment decided according to location |
| 12. Prevention | Removal of adenomas at colonoscopy, participation in national screening, diet, exercise and weight management, smoking cessation and limiting alcohol |
| 13. References | Heald RJ et al. Lancet 1986 and 9 other papers |
The rectosigmoid junction (RS junction) is the transition zone between the sigmoid colon and the rectum, anatomically the part of the large intestine about 5–15 cm above the peritoneal reflection. Malignant tumors arising at this site are classified separately in ICD-10 as C19 (rectosigmoid junction), covering the boundary zone between C18 (colon) and C20 (rectum). Because the anatomic and clinical boundaries are ambiguous, there is controversy over whether to classify the tumor as rectal cancer (C20) or colon cancer (C18) when deciding on treatment.
An important turning point in the history of colorectal cancer surgery was the establishment of Total Mesorectal Excision (TME) by Heald et al. in 1986. TME completely removes the rectum and the surrounding mesorectum, dramatically lowering local recurrence rates, and became the gold standard of rectal cancer surgery. This principle is also extended to rectosigmoid junction cancer. In the 1980s–90s, preoperative radiotherapy (or CCRT) was shown to be effective in reducing local recurrence in rectal cancer, which also influenced treatment decisions for cancers of the upper rectum and rectosigmoid junction.
In Korea, rectosigmoid junction cancer is managed as part of overall colorectal cancer statistics, and site-specific treatment principles are presented in the guidelines of the Korean Society of Coloproctology and the Korean Colorectal Cancer Study Group. With the spread of laparoscopic and robotic rectal resection, outcomes of minimally invasive surgery for cancers at this site have improved since the 2000s. Whether to apply neoadjuvant radiotherapy (or CCRT) under a rectal cancer protocol or to perform surgery alone under a colon cancer protocol for rectosigmoid junction cancer requires an individualized multidisciplinary decision.
The causes of rectosigmoid junction cancer are exactly the same as those of colon cancer (C18) and rectal cancer (C20), all sharing the common risk factors of colorectal adenocarcinoma. Among dietary factors, excessive intake of red and processed meat, lack of dietary fiber and insufficient vegetables and fruit increase risk. The longer dwell time of stool in the sigmoid colon and rectum, which increases the time carcinogens are in contact with the mucosa, has been proposed as a mechanism contributing to cancer development at this site. Obesity raises risk through insulin resistance, elevated IGF-1 and chronic inflammation, and physical inactivity raises risk independently.
Alcohol consumption accelerates colorectal adenoma formation and cancer development through acetaldehyde, a metabolite of alcohol, and smoking does so through tobacco carcinogens and tumor promoters. Some studies report that smoking shows a stronger association particularly with adenomas and sigmoid and rectal lesions. Inflammatory bowel disease (IBD), especially ulcerative colitis, generally increases colorectal cancer risk in patients with pancolitis. This also applies to this site. Diabetes, obesity and insulin resistance are also risk factors.
Hereditary predisposition: Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) increases cancer risk throughout the colon, including the sigmoid colon and rectosigmoid junction. FAP (APC mutation) causes adenomatous polyposis of the entire large intestine followed by malignant change. A family history (colorectal cancer in a first-degree relative) roughly doubles the risk. MUTYH-associated polyposis (MAP) is inherited in an autosomal recessive manner and causes multiple adenomas and colorectal cancer.
The molecular genetic features of rectosigmoid junction cancer resemble those of colon cancer (C18), especially sigmoid colon cancer. The conventional adenoma–carcinoma pathway (CIN pathway) is the most common, and the main somatic mutations are APC (about 75–80%), KRAS (about 40–45%), TP53 (about 45–55%), SMAD4/DCC (about 15–20%) and PIK3CA (about 15%). KRAS mutations tend to be reported at a somewhat higher rate in sigmoid and rectal lesions. MSI-H is observed in about 10–15% and provides the basis for immune checkpoint inhibitor therapy. BRAF V600E mutation is associated with sporadic MSI-H and carries a poor prognosis.
In Lynch syndrome–associated rectosigmoid junction cancer, a germline mutation in one of the MMR genes (MLH1, MSH2, MSH6, PMS2) is identified. In these cases, cancer develops at a relatively young age of 25–50 years at diagnosis. On whole-genome analysis, colorectal cancers of rectal and sigmoid origin show higher rates of KRAS mutation and the CIN pathway and lower rates of BRAF mutation and MSI-H than right-sided colon cancers. This is important in deciding treatment strategy. In the CMS classification, CMS2 (WNT and MYC activation, predominantly left-sided colon) is common at this site.
Treatment-related molecular markers: anti-EGFR antibody therapy is possible in RAS (KRAS, NRAS) wild-type tumors. BEACON regimen for BRAF V600E mutation. First-line pembrolizumab for MMR/MSI-H. Trastuzumab combination is possible for HER2 amplification (about 2–5%). NTRK fusions are rare but are targets of larotrectinib therapy. Pharmacogenomics: DPYD variants (5-FU toxicity) and UGT1A1 variants (irinotecan toxicity) are used in personalized chemotherapy planning.
Rectosigmoid junction cancer (C19) is estimated to account for about 10–15% of all colorectal cancers (C18–C20). Although it has its own ICD-10 code, in clinical practice and research it is often analyzed together with colon cancer (C18) or rectal cancer (C20), so incidence statistics for C19 alone are limited. Considering that more than about 30,000 colorectal cancers occur in Korea each year, C19 is estimated to reach several thousand cases per year. The sigmoid and rectosigmoid region has many bends within the large intestine and is where stool solidifies and stays for a long time, so the contact time of carcinogens with the mucosa is long. For this reason, the sigmoid colon and rectum are the main sites, where about 55–60% of all colorectal cancers arise.
By sex, it is 1.5–2 times more common in men than in women, and by age it increases sharply after 50 and is most common in the 60s–70s. In the rising trend of early-onset colorectal cancer under age 50, the sigmoid colon and rectosigmoid junction are also major sites. Geographically, as with colon and rectal cancer, incidence is high in cultures with a Westernized diet, and it is also increasing rapidly in East Asia, including Korea and Japan. With the expansion of national screening programs, the early detection rate tends to increase.
In patients with Lynch syndrome, the sigmoid colon and rectosigmoid junction fall within the general distribution of Lynch-associated cancers, which can arise anywhere in the colon; right-sided predominance (cecum, ascending colon) is more characteristic, but cancers also arise from the sigmoid colon downward. In FAP, adenomas are distributed throughout the large intestine, so this site is also included.
The pathogenesis of rectosigmoid junction cancer follows the same three molecular pathways as colon cancer (C18) and rectal cancer (C20) (the conventional CIN pathway, the serrated pathway and the MMR-deficiency pathway). Because of left-sided colon characteristics, the conventional CIN pathway is overwhelmingly predominant, with multistep carcinogenesis — APC mutation → adenoma → accumulation of KRAS→SMAD4→TP53 mutations → invasive adenocarcinoma — occurring in about 65–70%. The anatomic features of the sigmoid colon and rectosigmoid junction (narrow lumen, solid stool, long transit time) are thought to prolong the contact time of carcinogens with the mucosa, increasing the risk of carcinogenesis.
The serrated pathway (BRAF V600E → CIMP → MLH1 methylation → MSI-H serrated adenoma) is relatively less common at this site but does occur. Endoscopic detection and removal of sessile serrated adenomas/polyps (SSA/P) is important for preventing cancer through this pathway. The Lynch syndrome–associated MMR-deficiency pathway occurs throughout the large intestine, so this site is also included. The role of the microbiome is also gaining attention in the sigmoid colon and rectum; accumulation of Fusobacterium nucleatum has been observed in colon cancer mucosa and is reported to be involved in promoting carcinogenesis.
Tumor angiogenesis (VEGF/VEGFR), epithelial–mesenchymal transition (EMT), lymphovascular invasion and perineural invasion progress during invasion and metastasis. Because the rectosigmoid junction lies near the peritoneal reflection, peritoneal dissemination is possible when the tumor invades the peritoneum. Lymph node metastasis from cancers at this site mainly passes through the lymph nodes around the inferior mesenteric vessels.
The symptoms of rectosigmoid junction cancer are intermediate between those of left-sided colon cancer and rectal cancer. Because it lies between the sigmoid colon and rectum, stool passes through this site already solidified, and because of the relatively narrow lumen, a change in bowel habits often appears from early on. Alternating constipation and diarrhea and narrowing of stool caliber (pencil-thin stool) are characteristic. Bloody stools (bright red blood or bloody mucus) are also a common symptom and may be confused with anal bleeding or hemorrhoids, delaying diagnosis. In people aged 40 and over with bloody stools, colonoscopic evaluation should come first rather than presuming hemorrhoids.
Abdominal pain is crampy or squeezing in character, appears mainly in the lower or left abdomen, and is characteristically relieved temporarily after defecation. As the disease progresses, bowel obstruction develops, with abdominal distension, nausea, vomiting and cessation of bowel movements. Tenesmus and a sensation of pressure during defecation appear when the lower rectum is involved, but can also occur with large tumors at the rectosigmoid junction. Weight loss, fatigue (anemia) and loss of appetite accompany the disease. Because its location makes preservation of anal function after anterior resection easier than for distal rectal cancer, the functional outcome after surgery is relatively good. Rarely, when the tumor is adjacent to the bladder or uterus, bladder irritation symptoms (frequency, painful urination) may occur.
Physical findings of rectosigmoid junction cancer vary with the degree of progression. Early on there are no specific findings. On digital rectal examination (DRE), the rectosigmoid junction is mostly beyond the reach of the finger (15–20 cm from the anal verge), so direct palpation is difficult. However, DRE should always be performed to distinguish it from rectal cancer and to assess abnormal findings in the pelvis. A palpable lower or left lower abdominal mass on abdominal palpation suggests an advanced lesion. Abdominal distension, hyperactive bowel sounds (with partial obstruction) and tympany are observed.
Blood tests show anemia (chronic bleeding), hypoalbuminemia and elevated CEA. CEA is used for follow-up after a baseline value is established before treatment. Hepatomegaly (liver metastasis), left supraclavicular lymphadenopathy (Virchow's node, distant metastasis) and ascites (peritoneal metastasis) are signs of advanced disease. Colonoscopy shows a protruding, ulcerative or circumferential tumor at the rectosigmoid junction. Contrast-enhanced pelvic MRI is useful for assessing invasion below the peritoneal reflection, neurovascular invasion and proximity to adjacent organs (bladder, uterus, prostate). Results of MMR protein IHC, MSI, RAS and BRAF testing are directly reflected in the treatment plan.
Screening for rectosigmoid junction cancer is included in the same national colorectal cancer screening program as colon cancer (C18). Men and women aged 50 and over undergo an annual fecal occult blood test (iFOBT), and if positive, the entire large intestine is evaluated by colonoscopy. The sigmoid colon and rectosigmoid junction can also be observed with flexible sigmoidoscopy, but in Korea colonoscopy, which evaluates the entire large intestine, is the standard follow-up test. The rectosigmoid junction is easily accessible endoscopically, so the likelihood of early detection is high.
In high-risk groups, colonoscopy is performed earlier and at shorter intervals than in the general population. For Lynch syndrome, colonoscopy every 1–2 years from age 20–25 is recommended, and for FAP, annual colonoscopy from puberty. With a family history involving the sigmoid colon or rectosigmoid junction (colorectal cancer or adenoma in an immediate family member before age 50), early screening is recommended from 10 years before the family member's age at onset or from age 40. Flexible sigmoidoscopy screens only the rectosigmoid junction and sigmoid colon and is less comprehensive than colonoscopy, which evaluates the entire large intestine. Therefore, colonoscopy is recommended in the Korean national screening system.
Stool DNA testing (such as Cologuard) is a new technology that screens for colorectal cancer by detecting KRAS, NRAS and TP53 mutations and SEPT9 methylation in blood or stool. It can also detect lesions of the sigmoid colon and rectosigmoid junction, but it has not yet been introduced into national screening in Korea.
Rectosigmoid junction cancer is confirmed by colonoscopy + tissue biopsy. The rectosigmoid junction is accessible by both sigmoidoscopy and colonoscopy, but colonoscopy is recommended for simultaneous evaluation of lesions throughout the large intestine. When biopsy of a suspicious lesion confirms adenocarcinoma, RAS (KRAS, NRAS), BRAF V600E, MMR protein IHC (or MSI PCR/NGS), HER2 and NTRK fusion testing is performed. This is essential for selecting therapeutic targets in metastatic disease.
Staging imaging: abdominal, pelvic and chest CT (evaluation of distant and lymph node metastasis), contrast-enhanced pelvic MRI (invasion below the peritoneal reflection, T-stage subclassification, neurovascular invasion). Because the rectosigmoid junction lies near the peritoneal reflection, confirming by MRI whether the tumor is above (colonic features) or below (rectal features) the peritoneal reflection is important for treatment planning. PET-CT is used as a complement for detecting distant metastasis. AJCC 8th edition TNM staging applies the same criteria as colon cancer (C18). The baseline CEA level must be checked. Multidisciplinary evaluation is needed before surgery to determine the feasibility of total mesorectal excision and the surgical approach.
Treatment of rectosigmoid junction cancer applies principles intermediate between colon and rectal cancer treatment, and the exact location of the tumor (above or below the peritoneal reflection) is decisive for the treatment strategy. Lesions above the peritoneal reflection (sigmoid features) are treated as colon cancer, with surgery (sigmoid colectomy or left hemicolectomy) followed by adjuvant chemotherapy if needed. Preoperative radiotherapy (neoadjuvant therapy) is generally not needed. For lesions below or at the border of the peritoneal reflection, rectal cancer treatment principles (neoadjuvant CCRT → surgery → adjuvant chemotherapy) apply, and particularly for T3–T4 or N+ lesions, preoperative radiotherapy (CCRT or short-course radiation) lowers local recurrence rates.
In principle, surgery is anterior resection or low anterior resection aiming at sphincter preservation, with TME (total mesorectal excision) applied. Laparoscopic and robotic surgery achieve long-term outcomes equivalent to open surgery. If the anal sphincter is not involved, anastomosis is possible without a permanent stoma. After surgery for stage III disease, 6 months of FOLFOX or CAPOX is the standard adjuvant chemotherapy. Treatment of metastatic (stage IV) disease is the same as for colon cancer (C18): FOLFOX or FOLFIRI ± bevacizumab/cetuximab, pembrolizumab for MSI-H, and the BEACON regimen for BRAF V600E.
The prognosis of rectosigmoid junction cancer (C19) is similar to that of colon cancer. 5-year survival by stage: stage I about 90% or more, IIA about 83–87%, IIB about 72–77%, IIIA about 80%, IIIB about 60%, IIIC about 42%, IVA about 20–25%, IVB about 15%, and IVC (peritoneal metastasis) about 5–10%. These figures are derived from pooled colon and rectal cancer data, and large prognostic studies of C19 alone are limited. In general, rectosigmoid junction cancer has a lower local recurrence rate than rectal cancer and a higher likelihood of preserving anal function.
Prognostic factors include stage, status of the distal and circumferential resection margins (CRM) after TME, number of lymph node metastases, vascular, lymphatic and perineural invasion, and molecular markers (RAS, BRAF, MMR/MSI, HER2). MSI-H tumors have a good prognosis in stages II–III and derive no benefit from adjuvant 5-FU alone. BRAF V600E–mutated metastatic disease has a poor prognosis. A negative resection margin (R0) is the most important surgical prognostic factor. A change in CEA from baseline after treatment can signal recurrence early. Recurrence occurs mainly in the liver, lungs, peritoneum and local intra-abdominal lymph nodes. Systematic follow-up for 5 years after treatment (CEA every 3–6 months, CT every 6–12 months) is needed.
Prevention of rectosigmoid junction cancer follows the same principles as for colon cancer (C18) and rectal cancer (C20). Participation in national colorectal cancer screening (age 50 and over, fecal occult blood test → colonoscopy) is the most effective means of prevention. Immediate endoscopic resection of adenomas found at colonoscopy can prevent cancer at this site. Sessile serrated adenomas (SSA/P) are also precancerous lesions and must be removed. Adhering to surveillance intervals after endoscopic removal is important. In high-risk groups with Lynch syndrome or FAP, early endoscopic surveillance detects adenomas and cancers at this site early.
Dietary prevention: a diet rich in dietary fiber (whole grains, vegetables, fruit, legumes), minimal intake of red and processed meat, and sufficient intake of calcium and vitamin D are recommended. Regular physical activity (150 minutes or more of aerobic exercise per week) shortens colonic transit time and lowers insulin resistance, reducing the mucosal contact time of carcinogens. Preventing obesity and smoking cessation and limiting alcohol also contribute to risk reduction. Appropriate glycemic control in diabetes may also help lower colorectal cancer risk. Aspirin has been reported to reduce colorectal adenomas and cancer, but general preventive use is not recommended. Because early-onset colorectal cancer at younger ages (50 and under) is increasing, colonoscopy before age 40 is appropriate for those with a family history or symptoms.